You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Bulk Pharmaceutical API Sources for metoprolol tartrate


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for metoprolol tartrate

Vendor Vendor Homepage Vendor Sku API Url
Sigma-Aldrich ⤷  Start Trial M5391_SIGMA ⤷  Start Trial
NovoSeek ⤷  Start Trial 441308 ⤷  Start Trial
MP Biomedicals ⤷  Start Trial 190018 ⤷  Start Trial
MolPort ⤷  Start Trial MolPort-003-983-883 ⤷  Start Trial
Alsachim ⤷  Start Trial 1018 ⤷  Start Trial
ABI Chem ⤷  Start Trial AC1L9AY1 ⤷  Start Trial
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk API Sources for Metoprolol Tartrate

Last updated: February 19, 2026

Metoprolol tartrate, a beta-blocker used for cardiovascular conditions, is manufactured globally. The API sourcing landscape includes a mix of large-scale pharmaceutical producers, contract manufacturing organizations (CMOs), and import/export markets. This analysis covers primary regions, key manufacturers, and market dynamics.

Major API Manufacturing Regions

  • India: Leading global supplier, with prominent API manufacturers exporting to North America and Europe.
  • China: Significant capacity increases over recent years, high-volume low-cost manufacturing.
  • Europe: Focused on high-quality, FDA-approved sources, mainly for regulatory-compliant APIs.
  • United States: Limited domestic manufacturing; primarily APIs are imported.

Key API Manufacturers and Suppliers

Company Name Location Certifications Production Capacity Notes
Sagent Pharmaceuticals India WHO-GMP, USDMF High Consistent supply, regulatory compliant
Hetero Labs India USDMF, EUGMP Large Significant export volume, low-cost manufacturing
Zhejiang Huahai Pharmaceuticals China CE, USDMF Large Known for cost-effective production, compliant with US/EU regulations
Aurobindo Pharma India USDMF, EUGMP High Integrated R&D and manufacturing capabilities
Teva Pharmaceuticals Israel USDMF, EUGMP High Focus on quality, global distribution
Cipla India USDMF, EUGMP Moderate to high Diversified API portfolio

Regulatory and Quality Considerations

  • GMP Compliance: Most suppliers adhere to Good Manufacturing Practices, especially when targeting US and EU markets.
  • Regulatory Filings: Suppliers with Active Drug Master Files (DMFs) registered with FDA or CEPs with the European Medicines Agency hold higher market relevance.
  • Quality Standards: Suppliers maintaining ISO certifications and testing for residual solvents, heavy metals, and polymorphs meet stringent quality standards.

Supply Chain Dynamics

  • Price Trends: Chinese APIs tend to offer lower costs compared to Indian and European sources.
  • Lead Times: European and US sources often have longer lead times due to regulatory and quality assurance processes.
  • Capacity Constraints: Disruptions, such as those from the COVID-19 pandemic, impacted production capacity, but recovery is now evident.
  • Contract Manufacturing: Many generic drug companies rely on CMOs in Asia for large-scale API supply.

Import-Export Market

  • Major Importers: US, EU, and Japan primarily import APIs from India and China.
  • Exporters: India and China rank as top export sources, with India exporting approximately 60% of APIs globally (Frost & Sullivan, 2022).

Key Considerations for Procurement

  • Confirm supplier regulatory filings, including USDMF/CEP.
  • Ensure supplier compliance with the target market’s regulatory standards.
  • Evaluate supply stability and production capacity, especially in geopolitical or pandemic-related disruptions.
  • Prioritize suppliers with a track record of quality and consistent supply.

Summary

The API market for metoprolol tartrate is dominated by Indian and Chinese manufacturers providing large volumes at competitive prices. European and US sources prioritize regulatory compliance and quality. Global procurement strategies should weigh cost against regulatory requirements, supply reliability, and quality assurance.


Key Takeaways

  • Indian and Chinese suppliers dominate global API sourcing for metoprolol tartrate.
  • Regulatory compliance (USDMF, CEP) influences supplier selection for regulated markets.
  • Cost advantages from China are tempered by longer lead times and quality assurance needs.
  • European sources focus on high compliance standards but have limited capacity.
  • Supply disruptions are gradually resolving, with China and India resuming steady production.

FAQs

1. Which countries are the top suppliers of metoprolol tartrate API?
India and China lead production and export, with India accounting for approximately 60% of global API exports.

2. How do regulatory standards influence sourcing decisions?
Suppliers with USDMFs or CEPs are preferred for US and EU markets due to compliance requirements, ensuring regulatory approval and quality.

3. Are Chinese API suppliers reliable?
Many Chinese suppliers have large capacities and meet international standards, but quality and regulatory compliance vary. Verification and audits are recommended.

4. What are the primary cost considerations in sourcing API?
Cost differential favors Chinese manufacturers, but factors include lead time, regulatory compliance costs, and quality assurance.

5. How has COVID-19 impacted API supply chains?
Disruptions caused capacity constraints; supplies are stabilizing but require ongoing supplier audits and contingency planning.


References

  1. Frost & Sullivan. (2022). Global Pharmaceutical API Market Report.
  2. U.S. Food and Drug Administration. (2023). Drug Master Files Database.
  3. European Medicines Agency. (2023). Certified Copies of EUDMF and CEPs.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.